Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm in there buying anything under 7, picked up about $7,000 already.
Recent times have seen a recovery for Humanigen (HGEN) stock; shares are up by 33% over the past month, following September’s sharp drop. Recall, shares took a tumble after the FDA spurned lenzilumab – the company’s drug candidate to treat hospitalized Covid-19 patients – with the regulatory body saying it required additional data before moving forward.
Meanwhile, the company is pursuing opportunities elsewhere and hoping to get the drug approved in the UK.
At the start of October, Humanigen submitted to the MHRA (The Medicines and Healthcare products Regulatory Agency) its Marketing Authorization Application (MAA).
Oppenheimer’s Kevin DeGeeter thinks the treatment has a good chance of making the grade.
“Our positive outlook for conditional approval of lenzilumab in UK for COVID is based on recent track record of MHRA drawing independent conclusions from FDA on COVID therapies and UK focus on C-reactive protein (CRP) as prognostic for COVID patients,” the 5-star analyst explained. “CRP subgroup analysis from LIVE-AIR study demonstrated statistically significant improvements on incidence of mechanical ventilator or death vs. placebo.”
All News
Humanigen: All You Need to Know Right Now
?Marty Shtrubel
Nov 05, 2021, 06:04 AM
AA
?
Recent times have seen a recovery for Humanigen (HGEN) stock; shares are up by 33% over the past month, following September’s sharp drop. Recall, shares took a tumble after the FDA spurned lenzilumab – the company’s drug candidate to treat hospitalized Covid-19 patients – with the regulatory body saying it required additional data before moving forward.
Meanwhile, the company is pursuing opportunities elsewhere and hoping to get the drug approved in the UK.
At the start of October, Humanigen submitted to the MHRA (The Medicines and Healthcare products Regulatory Agency) its Marketing Authorization Application (MAA).
Oppenheimer’s Kevin DeGeeter thinks the treatment has a good chance of making the grade.
“Our positive outlook for conditional approval of lenzilumab in UK for COVID is based on recent track record of MHRA drawing independent conclusions from FDA on COVID therapies and UK focus on C-reactive protein (CRP) as prognostic for COVID patients,” the 5-star analyst explained. “CRP subgroup analysis from LIVE-AIR study demonstrated statistically significant improvements on incidence of mechanical ventilator or death vs. placebo.”
Considering lenzilumab’s anti-inflammation MOA (mechanism of action), DeGeeter sees the CRP level as “reasonable patient stratification criteria.” If the treatment gains approval, based on presents case rates, all of HGEN’s current lenzilumab inventory could be heading the UK’s way.
However, one possible risk is that the MHRA will hold out until late 1Q22 with its decision. This is when Humanigen is expected to present data from the ACTIV5 study.
To-date, enrollment is 75% complete, up from mid-September’s 60%, and DeGeeter expects completion by the end of the year. The study’s primary endpoint is incidence of mechanical ventilation or death, compared to LIVE-AIR’s survival without ventilation. DeGeeter also counts the secondary endpoint of time-to-recovery as an “important” factor too.
With the UK decision a potential near-term catalyst, the Oppenheimer analyst sticks with an Outperform (i.e., Buy) rating and a bullish price target; at $17, the figure could generate returns of 107% over the one-year timeframe. (To watch DeGeeter’s track record.
All News
Humanigen: All You Need to Know Right Now
?Marty Shtrubel
Nov 05, 2021, 06:04 AM
AA
?
Recent times have seen a recovery for Humanigen (HGEN) stock; shares are up by 33% over the past month, following September’s sharp drop. Recall, shares took a tumble after the FDA spurned lenzilumab – the company’s drug candidate to treat hospitalized Covid-19 patients – with the regulatory body saying it required additional data before moving forward.
Meanwhile, the company is pursuing opportunities elsewhere and hoping to get the drug approved in the UK.
At the start of October, Humanigen submitted to the MHRA (The Medicines and Healthcare products Regulatory Agency) its Marketing Authorization Application (MAA).
Oppenheimer’s Kevin DeGeeter thinks the treatment has a good chance of making the grade.
“Our positive outlook for conditional approval of lenzilumab in UK for COVID is based on recent track record of MHRA drawing independent conclusions from FDA on COVID therapies and UK focus on C-reactive protein (CRP) as prognostic for COVID patients,” the 5-star analyst explained. “CRP subgroup analysis from LIVE-AIR study demonstrated statistically significant improvements on incidence of mechanical ventilator or death vs. placebo.”
Considering lenzilumab’s anti-inflammation MOA (mechanism of action), DeGeeter sees the CRP level as “reasonable patient stratification criteria.” If the treatment gains approval, based on presents case rates, all of HGEN’s current lenzilumab inventory could be heading the UK’s way.
However, one possible risk is that the MHRA will hold out until late 1Q22 with its decision. This is when Humanigen is expected to present data from the ACTIV5 study.
To-date, enrollment is 75% complete, up from mid-September’s 60%, and DeGeeter expects completion by the end of the year. The study’s primary endpoint is incidence of mechanical ventilation or death, compared to LIVE-AIR’s survival without ventilation. DeGeeter also counts the secondary endpoint of time-to-recovery as an “important” factor too.
With the UK decision a potential near-term catalyst, the Oppenheimer analyst sticks with an Outperform (i.e., Buy) rating and a bullish price target; at $17, the figure could generate returns of 107% over the one-year timeframe.
Looking at the consensus breakdown, based on 4 Buys, in addition to 1 Hold and Sell, each, the analyst consensus rates this stock a Moderate Buy. That said, the average price target is no less bullish than DeGeeter’s; in fact, at $17.25 it is even slightly higher.
I just have a question for all of you, what company/companies is Avid most valuable to?
And why would anybody pay more than that company?
I just don't believe Halo wants avid in the hands of somebody else. Average manufacturing capabilities have been crucial.
No doubt!
The only company that would buy us out at this point would be HALO.
It looks like it would be a wonderful one stock transaction. Or half cash half stock.
It's a runaway train now we're going higher next stop nine then 10:00.
Just came aboard with 25,000.
You got to catch it with a confluence of events. It's going over to most likely today.
I just bought 10,000 shares too 1.22. the development of all those new stores should easily push the stock to three or four dollars.
The q should be strong. HGEN out of the q...
Net loss for the three months ended June 30, 2021 was $70.8 million or $1.20 per share as compared to $24.0 million or $0.79 per share for the three months ended June 30, 2020. The net loss for the six months ended June 30, 2021 was $136.4 million or $2.45 per share as compared to $26.5 million or $1.00 per share for the six months ended June 30, 2020. The increase in net loss for both periods was largely due to an increase in total expenses, mainly Research and Development (“R&D”) expense which rose significantly as the company accelerated its efforts to manufacture lenzilumab for potential commercialization upon a regulatory authorization. R&D expense increased $41.9 million.
Trading professionally for 20 years well over 10,000 stocks and I still have never sold at the top.
As far as filling gaps, most of the time the Gap that needs filling is the one between one's ears.
All in fun!
Everything looks right here, guess I'll pick up 10,000 tomorrow morning.
Too concerns I do have, the volume is a little crazy considering the float and it's foreign company. Anybody have any answers?
This is a fine biotech with a lot of promising technology. Too many people were counting on early approval and it didn't happen I'm consequently the quick money folks sold off and dropped this way below where we should be. I think I bought my first shares at 15 bought more at 6, and added today.
A man after my own heart. Quantum physics!
It's hell being an observer isn't it?
Entanglement, superposition, quantum tunneling, string theory, is most of what I study.
A really deep challenge!
If I could just find that dark Matter I might be getting somewhere with all this.
One way that really pisses me off, that they can get out of a short by buying shares direct from the company. The problem is that most likely it's the same guys who did funding before. I don't have any doubt that you're right about that's the only way they can cover.
Just take a look at some of the buying that went through an aftermarket 10,000 20,000 All above 28. No doubt we'd be 35 to 40 if they had to cover normally.
Next few days should be really crazy, with us moving up and down and I believe will go over 30. Last time I had a stock do this was 21 years ago. A lot of the shares changed hands at One price. This is going to be a little different with such high institutional percentage and shorts making up together well over 100%. I pity the fool that got in short today and wakes up tomorrow with a margin call. Only quantum physics will help him, he needs to be in superposition.
The beast rises again.
I just have to buy 19. This is just too big of hit on solid earnings report.
I'm bleeding with confidence that is going back up.
I have to be due some good luck. Half my roof is gone, power is scarce and I'm a senior citizen with two babies in diapers due to the storm.
I just hit the app this a.m. that exactly 8:30 my time. I saw the big drop in hell I just bought.
Let me tell you, it's almost impossible to get a roofer
Did you do the conference cal,l what happened? I'm completely in the dark, no pun intended.
.
It must be Chicken Little selling out. Panic selling on small volume.
It's been going down for the last 2 weeks + but still I'm undeterred. I'm buying but no margin. This nonsense can really irrational.
Screw it. Just picked up 5K all in the 20+... It's irrational and it has to get back to being rational.
I hear you. Don't sell yourself out, it's going past 50.
Come on I'm ready to buy some 22s.
Anything under 23 I'm nibbling too.
Anyone buying options now?
What do you guys think of the best options around?
What are you guys think, April 22 at $4.70? I think I'm going to pull the trigger soon.
Yep that's a big winner! Thanks for bringing that to our attention.
You're reading my mind. I've been looking at those $20 options myself. Could be a massive money maker.
Did you get anything on the bid on those options...
I guess what I'm asking is it worth sitting on the bid?
It's completely insane. The float is so tied down that to get in or out you're talking dollars and that's a small position compared to some of these institutional investors.
Great piece of work, good job. I would like to be able to do that but the tax situation would absolutely kill me. The prophet will go straight to the government.
I'm buying the 23's, ...
Sounds about right.
We're looking good and we will be looking better when HGEN gets approval.
Looking Good!
With institutional investors taking almost all the shares, very difficult to go down much. They're always willing to add shares on a drop so that number will most likely go up even with some institutions selling out.
There's just too few of shares for everybody to get a piece of the pie.
I'm bleeding with confidence with HGEN......
Let me tell you my level of confidence!
I'm putting a mortgage on my properties to buy 20,000 more shares.
Covid it's not going away, in fact, it's headed up.
With Trump's skullduggery and foolishness on the vaccine, there will be more than enough people that will need the medication. It's critical.
I've worked booths for a few companies mostly on the OTC.
I did work the CES in Las Vegas with macromedia before it was bought many years ago.
You're not going to build a lot of relationships with that kind of presentation.
We're all in agreement on this, I Say we're close to the bullseye on what's happening with that.
Let's not take away how important it is to be upbeat, personable sounding, friendly and all around fun to be around. The way he's presenting this I don't even know if I want to be around this guy. People buy from people they like
People do business with people they like. Sometimes it's not about the money.
We're fortunate that we're in a specialized business and that this gentleman isn't making the sales of the product.
I guess the best question I could ask all of y'all is would you buy anything from the guy. But saying all that we do have a lock-in product I believe.
We do a good job and we're dependable and supposedly one of the best in the business.
ArchieK
That's the problem, he put you to sleep whether you're a scientist or not. There are probably a lot of eighth graders that could have done a lot better job.
If I was running the company, no way in hell would I have him making that presentation.
We have to face some facts, we're a billion dollar company not an OTC penny stock.
That being said I don't think it was that detrimental. When we have that kind of product, that's not that much downside to a hyperweak presentation.